Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone
metastases and no known visceral metastatic disease. However, very few data have been
reported in patients with mCRPC who are asymptomatic or mildly symptomatic. Recently, results
from an International Expanded Access Program have also suggested a benefit of radium-223 in
asymptomatic patients with mCRPC. In addition, the mechanism of action of radium-223 should
not be correlated with the presence/absence of the AR-V7 mutation, although this issue has
not yet been evaluated.
The aim of this study is to assess the efficacy of radium-223 in asymptomatic patients with
mCRPC, and to establish the association between AR-V7 status and radium-223 activity.